Alumis
Alumis Logo
About Alumis
Alumis Inc is a clinical stage biopharmaceutical company focused on developing precision therapies for immune-mediated diseases. The company is advancing a pipeline of novel oral drug candidates, including ESK-001, a selective TYK2 inhibitor for conditions such as plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis, and A-005, a central nervous system-penetrant TYK2 inhibitor for neuroinflammatory and neurodegenerative diseases. Alumis aims to transform the treatment paradigm for patients by replacing broad immunosuppression with targeted therapies that address immune dysfunction and improve clinical outcomes. The company operates in the United States and is headquartered in South San Francisco, California.
Address
280 East Grand Avenue,
South San Francisco, 94080
United States
Year founded
2021
Number of employees
100-200
Sector
Health Care
Industry Group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Biotechnology
Report inaccurate data
Request an update to help us keep the brand up-to-date.
